Clinical trial
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced…
NCT00499265 · Heidelberg Pharma AG, Industry · Completed
Key facts
| NCT number | NCT00499265 |
|---|---|
| Title | Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery |
| Official title | A Randomized, Open Label, Phase II Proof of Concept Study of WX-671 in Combination With Gemcitabine vs.Gemcitabine Alone in Patients With Locally Advanced, Non Resectable Pancreatic Cancer in Order to Evaluate the Anti-Tumor Activity of the Combination Therapy |
| Lead sponsor | Heidelberg Pharma AG, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671 |
| Enrollment | 95 |
| Start date | Apr 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Jul 11, 2007 |
| Last update posted | Mar 29, 2012 |
| Countries | Germany, Hungary, Italy, Russia, Spain, Ukraine |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: